HNSA Stock Overview
A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 29.84 |
| 52 Week High | SEK 57.30 |
| 52 Week Low | SEK 21.96 |
| Beta | 1.46 |
| 11 Month Change | -26.32% |
| 3 Month Change | -30.41% |
| 1 Year Change | 8.67% |
| 33 Year Change | -68.34% |
| 5 Year Change | -76.99% |
| Change since IPO | 171.27% |
Recent News & Updates
It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks
Nov 07
Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Oct 20Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%
Aug 24Recent updates
It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks
Nov 07Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Oct 20Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%
Aug 24Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%
Jul 23Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Jul 21Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package
Jun 21Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump
May 21Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates
Apr 05Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report
Feb 07Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing
Dec 28Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts
Oct 13Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?
Sep 22Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)
May 31Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt
Apr 03Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Feb 06Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023
Feb 01Shareholder Returns
| HNSA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.1% | -5.6% | -3.6% |
| 1Y | 8.7% | 17.3% | 12.3% |
Return vs Industry: HNSA underperformed the Swedish Biotechs industry which returned 19.4% over the past year.
Return vs Market: HNSA underperformed the Swedish Market which returned 13.4% over the past year.
Price Volatility
| HNSA volatility | |
|---|---|
| HNSA Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: HNSA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: HNSA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 135 | Søren Tulstrup | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
Hansa Biopharma AB (publ) Fundamentals Summary
| HNSA fundamental statistics | |
|---|---|
| Market cap | SEK 2.02b |
| Earnings (TTM) | -SEK 654.78m |
| Revenue (TTM) | SEK 189.39m |
10.7x
P/S Ratio-3.1x
P/E RatioIs HNSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSA income statement (TTM) | |
|---|---|
| Revenue | SEK 189.39m |
| Cost of Revenue | SEK 88.19m |
| Gross Profit | SEK 101.20m |
| Other Expenses | SEK 755.98m |
| Earnings | -SEK 654.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | -9.66 |
| Gross Margin | 53.43% |
| Net Profit Margin | -345.73% |
| Debt/Equity Ratio | -294.7% |
How did HNSA perform over the long term?
See historical performance and comparison